-
Sector Analysis
Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033. Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting...
-
Sector Analysis
Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
Type 2 diabetes (T2D), formerly known as non-insulin dependent or adult-onset diabetes, is a chronic condition characterized by a non-autoimmune progressive loss of pancreatic beta cells, which produce insulin (Lu et al., 2024; World Health Organization [WHO], 2024). T2D accounts for over 90% of all diabetes cases, with type 1 and gestational diabetes making up the majority of the remaining cases (Goyal, Singhal and Jialal, 2023). T2D most commonly occurs in persons older than 45 years, however its prevalence in...
-
Product Insights
Diabetic Foot Ulcers: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Diabetic Foot Ulcers - Global Clinical Trials Review, 2026" provides an overview of Diabetic Foot Ulcers Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Product Insights
Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Macular Edema - Global Clinical Trials Review, 2025" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Diabetic Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Nephropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Type 1 Diabetes in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033. This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.